Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury

Circulation

Volumn 120, Issue 8, 2009, Pages 677-686

  Korkmaz, Sevil ^a   Radovits, Tamás ^a,b   Barnucz, Eniko ^a   Hirschberg, Kristóf ^a,b   Neugebauer, Philipp ^a   Loganathan, Sivakkanan ^a   Veres, Gábor ^b   Páli, Szabolcs ^a,b   Seidel, Beatrice ^a   Zöllner, Stefan ^a   Karck, Matthias ^a   Szabó, Gábor ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Contractility; Genes; Myocardial infarction; Nitric oxide

Indexed keywords

3 NITROTYROSINE; BETA ACTIN; CINACIGUAT; CYCLIC GMP; CYCLOOXYGENASE 2; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; ISOPRENALINE; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE PRESSURE; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE ISCHEMIA; HEART MUSCLE RELAXATION; HEART PERFORMANCE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; OXIDATIVE STRESS; PRESSURE VOLUME CURVE; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION;

ADRENERGIC BETA-AGONISTS; ANIMALS; BENZOIC ACIDS; CARDIOTONIC AGENTS; CYCLIC AMP; CYCLIC GMP; CYCLOOXYGENASE 2; DOGS; FEMALE; GENE EXPRESSION; GUANYLATE CYCLASE; HEART FUNCTION TESTS; ISOPROTERENOL; L-LACTATE DEHYDROGENASE; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NITRIC OXIDE; PEROXYNITROUS ACID; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SURVIVAL RATE; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 69649087375     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.870774     Document Type: Article

References (38)

1. Moro MA, Russel RJ, Cellek S, Lizasoain I, Su Y, Darley-Usmar VM, Radomski MW, Moncada S. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A. 1996;93:1480-1485.
2. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H S AK, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Muller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B, Muller-Esterl W, Schmidt HH. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest. 2006;116:2552-2561.
3. Munzel T, Genth-Zotz S, Hink U. Targeting heme-oxidized soluble gua-nylate cyclase: solution for all cardiorenal problems in heart failure? Hypertension. 2007;49:974-976.
4. Feelisch M. The use of nitric oxide donors in pharmacological studies. Naunyn Schmiedebergs Arch Pharmacol. 1998;358:113-122.
5. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006;5: 755-768.
6. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M, Schroeder W, Schroder H, Stahl E, Steinke W, Wunder F. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol. 2002; 136:773-783.
7. Frey R, Muck W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G. Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers. J Clin Pharmacol. 2008;48:1400-1410.
8. Schmidt HH, Schmidt PM, Stasch JP. NO- and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol. 2009:309-339.
9. Rona G. Catecholamine cardiotoxicity. J Mol Cell Cardiol. 1985;17: 291-306.
10. Wexler BC. Myocardial infarction in young vs old male rats: pathophysiologic changes. Am Heart J. 1978;96:70-80.
11. Wexler BC, Greenberg BP. Effect of exercise on myocardial infarction in young vs. old male rats: electrocardiograph changes. Am Heart J. 1974; 88:343-350.
12. Chagoya de Sanchez V, Hernandez-Munoz R, Lopez-Barrera F, Yanez L, Vidrio S, Suarez J, Cota-Garza MD, Aranda-Fraustro A, Cruz D. Sequential changes of energy metabolism and mitochondrial function in myocardial infarction induced by isoproterenol in rats: a long-term and integrative study. Can J Physiol Pharmacol. 1997;75:1300-1311.
13. Singal PK, Dhalla AK, Hill M, Thomas TP. Endogenous antioxidant changes in the myocardium in response to acute and chronic stress conditions. Mol Cell Biochem. 1993;129:179-186.
14. Rajadurai M, Stanely Mainzen Prince P. Preventive effect of naringin on cardiac markers, electrocardiographic patterns and lysosomal hydrolases in normal and isoproterenol-induced myocardial infarction in Wistar rats. Toxicology. 2007;230:178-188.
15. Radovits T, Bomicke T, Kokeny G, Arif R, Loganathan S, Kecsan K, Korkmaz S, Barnucz E, Sandner P, Karck M, Szabo G. The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus. Br J Pharmacol. 2009;156: 909-919.
16. Szabo G, Soos P, Mandera S, Heger U, Flechtenmacher C, Bahrle S, Seres L, Cziraki A, Gries A, Zsengeller Z, Vahl CF, Hagl S, Szabo C. INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation. Shock. 2004;21:426-432.
17. Veres G, Radovits T, Schultz H, Lin LN, Hutter J, Weigang E, Szabolcs Z, Szabo G. Effect of recombinant aprotinin on postoperative blood loss and coronary vascular function in a canine model of cardiopulmonary bypass. Eur J Cardiothorac Surg. 2007;32:340-345.
18. Hirschberg K, Radovits T, Loganathan S, Entz L, Beller CJ, Gross ML, Sandner P, Karck M, Szabó G. Selective phosphodiesterase-5 inhibition reduces neointimal hyperplasia in rat carotid arteries after surgical end-arterectomy. J Thorac Cardiovasc Surg. 2009;137:1508-1514.
19. Liaudet L, Soriano FG, Szabo E, Virag L, Mabley JG, Salzman AL, Szabo C. Protection against hemorrhagic shock in mice genetically deficient in poly(ADP-ribose)polymerase. Proc Natl Acad Sci U S A. 2000;97:10203-10208.
20. Kass DA, Maughan WL, Guo ZM, Kono A, Sunagawa K, Sagawa K. Comparative influence of load versus inotropic states on indexes of ventricular contractility: experimental and theoretical analysis based on pressure-volume relationships. Circulation. 1987;76:1422-1436.
21. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch JP, Burnett JC Jr. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension. 2007;49:1128-1133.
22. Sabeena Farvin KH, Anandan R, Kumar SH, Shiny KS, Sankar TV, Thankappan TK. Effect of squalene on tissue defense system in isoproterenol-induced myocardial infarction in rats. Pharmacol Res. 2004;50:231-236.
23. Shimoike H, Iwai N, Kinoshita M. Differential regulation of natriuretic peptide genes in infarcted rat hearts. Clin Exp Pharmacol Physiol. 1997; 24:23-30.
24. Buttrick PM, Kaplan M, Leinwand LA, Scheuer J. Alterations in gene expression in the rat heart after chronic pathological and physiological loads. J Mol Cell Cardiol. 1994;26:61-67.
25. Schultz JE, Witt SA, Nieman ML, Reiser PJ, Engle SJ, Zhou M, Pawlowski SA, Lorenz JN, Kimball TR, Doetschman T. Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. J Clin Invest. 1999;104:709-719.
26. Yang XM, Philipp S, Downey JM, Cohen MV. Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol. 2006;101:311-318.
27. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, Seguchi O, Myoishi M, Minamino T, Ohara T, Nagai Y, Nanto S, Watanabe K, Fukuzawa S, Hirayama A, Nakamura N, Kimura K, Fujii K, Ishihara M, Saito Y, Tomoike H, Kitamura S. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007; 370:1483-1493.
28. Fujio N, Ohashi M, Nawata H, Kato K, Ibayashi H, Matsuo H. Relationship between atrial natriuretic polypeptide and cyclic 35-guanosine monophosphate in human plasma. J Lab Clin Med. 1987;109:706-710.
29. Michel JB, Mercadier JJ, Galen FX, Urbain R, Dussaule JC, Philippe M, Corvol P. Urinary cyclic guanosine monophosphate as an indicator of experimental congestive heart failure in rats. Cardiovasc Res. 1990;24: 946-952.
30. Hamet P, Pang SC, Tremblay J. Atrial natriuretic factor-induced egression of cyclic guanosine 3:5-monophosphate in cultured vascular smooth muscle and endothelial cells. J Biol Chem. 1989;264: 12364-12369.
31. Shinmura K, Xuan YT, Tang XL, Kodani E, Han H, Zhu Y, Bolli R. Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning. Circ Res. 2002;90:602-608.
32. Thompson NL, Bazoberry F, Speir EH, Casscells W, Ferrans VJ, Flanders KC, Kondaiah P, Geiser AG, Sporn MB. Transforming growth factor beta-1 in acute myocardial infarction in rats. Growth Factors. 1988;1: 91-99.
33. Saura M, Zaragoza C, Herranz B, Griera M, Diez-Marques L, Rodriguez-Puyol D, Rodriguez-Puyol M. Nitric oxide regulates transforming growth factor-beta signaling in endothelial cells. Circ Res. 2005; 97:1115-1123.
34. O'Banion MK. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol. 1999;13:45-82.
35. Dias-Junior CA, Souza-Costa DC, Zerbini T, da Rocha JB, Gerlach RF, Tanus-Santos JE. The effect of sildenafil on pulmonary embolism-induced oxidative stress and pulmonary hypertension. Anesth Analg. 2005;101:115-120. (Pubitemid 40853360)
36. Szabo C, Cuzzocrea S, Zingarelli B, O'Connor M, Salzman AL. Endo-thelial dysfunction in a rat model of endotoxic shock: importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite. J Clin Invest. 1997;100:723-735.
37. Karthick M, Stanely Mainzen Prince P. Preventive effect of rutin, a bioflavonoid, on lipid peroxides and antioxidants in isoproterenol-induced myocardial infarction in rats. J Pharm Pharmacol. 2006;58: 701-707.
38. Krieg T, Liu Y, Rutz T, Methner C, Yang XM, Dost T, Felix SB, Stasch JP, Cohen MV, Downey JM. BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts. Eur Heart J. 2009;30:1607-1613.